Research Grant
[Cite as https://purl.org/au-research/grants/nhmrc/552469]Researchers: Prof Maher Gandhi (Principal investigator) , Prof David Ritchie
Brief description The presence of Epstein-Barr virus (EBV) withiin EBV-positive malignant lymphoma cases provides a potential target for adoptive immunotherapy. Previous studies have established that adoptive immunotherapy for certain subtypes of lymphoma with EBV-specific killer T cells can lead to remission of disease. The objective of this study is to examine whether a similar strategy but using an enhanced methodology can be applied for the treatment of a range of relapsed-refractory EBV-positive lymphomas.
Funding Amount $AUD 324,397.29
Funding Scheme NHMRC Project Grants
Notes Standard Project Grant
- nhmrc : 552469
- PURL : https://purl.org/au-research/grants/nhmrc/552469
